Exane Derivatives Clovis Oncology, Inc. Transaction History

Exane Derivatives

  • $157 Million
  • Q2 2022

A detailed history of Exane Derivatives transactions in Clovis Oncology, Inc. stock. As of the latest transaction made, Exane Derivatives holds 166 shares of CLVS stock, worth $14. This represents 0.0% of its overall portfolio holdings.

Number of Shares
166
Previous 166 -0.0%
Holding current value
$14
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

Apr 17, 2020
SELL
$3.77 - $11.0 $7,291 - $21,274
-1,934 Reduced 92.1%
166 $1,000
Q2 2018

Jul 19, 2018
BUY
$42.06 - $62.4 $88,326 - $131,040
2,100 New
2,100 $0

Others Institutions Holding CLVS

# of Institutions
1
Shares Held
166
Call Options Held
0
Put Options Held
0
View Full List

About Clovis Oncology, Inc.

CLVS Quotes by TradingView
  • Ticker CLVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 144,480,000
  • Market Cap $13M
  • Description
  • Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...
More about CLVS
Track This Portfolio

Track Exane Derivatives Portfolio

Follow Exane Derivatives and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

News

Stay updated on Exane Derivatives with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email